Woodford who? TCR-focused Immunocore soldiers on with $130M+ B round
Immunocore — once a darling of the now-disgraced Neil Woodford — is shaking off its past by raising more than $130 million in a Series B haul.
The Oxfordshire, UK-based company, which launched in 2015 to advance its T cell receptor (TCR) technology with a mammoth $320 million round, was soon glorified with a valuation of nearly $1 billion (£800m). That unicorn status proved to be its Achilles heel, triggering an exodus of top management in recent years as potential investors balked at the old valuation.